论文部分内容阅读
目的探讨葡萄糖调节蛋白(GRP)78和GRP94蛋白在直肠腺癌的癌组织中的表达及其临床意义。方法收集直肠腺癌手术标本45例,常规石蜡包埋后切片,应用En Vision TM免疫组织化学法检测GRP78和GRP94蛋白在直肠腺癌的癌组织及相应癌旁组织中的表达水平。结果 1在45例直肠腺癌的癌组织中GRP78和GRP94蛋白表达阳性率明显高于其在对应的癌旁组织中的表达(GRP78:χ2=16.200,P<0.001;GRP94:χ2=14.221,P<0.001)。2 GRP78和GRP94蛋白在直肠腺癌的癌组织中的阳性表达均与病理分化类型、Dukes分期和淋巴结转移有关(P<0.05),尚未发现GRP78和GRP94蛋白在直肠腺癌的癌组织中的阳性表达与患者性别、年龄、肿瘤大小等临床特征有关(P>0.05)。3在24例GRP78蛋白表达阳性病例中,GRP94蛋白表达阳性者为18例,21例GRP78蛋白表达阴性病例中,GRP94蛋白表达阳性者为6例,两者在直肠腺癌中的表达呈正相关(rs=0.464,P<0.01)。结论 GRP78和GRP94蛋白在直肠腺癌的癌组织中呈高表达,并与其转移和侵袭有关,可作为判断直肠腺癌恶性程度的有用指标。
Objective To investigate the expression and clinical significance of glucose regulated protein (GRP) 78 and GRP94 protein in rectal adenocarcinoma of the cancerous tissues. Methods 45 cases of rectal adenocarcinoma were collected and paraffin-embedded and sliced. Envision TM immunohistochemistry was used to detect the expression of GRP78 and GRP94 protein in rectal adenocarcinoma tissues and adjacent tissues. Results 1 The positive rates of GRP78 and GRP94 in 45 cases of rectal adenocarcinoma were significantly higher than those in corresponding paracancerous tissues (GRP78: χ2 = 16.200, P <0.001; GRP94: χ2 = 14.221, P <0.001). The positive expression of GRP78 and GRP94 protein in rectal adenocarcinoma was correlated with the pathological type, Dukes stage and lymph node metastasis (P <0.05), and no positive expression of GRP78 and GRP94 protein in rectal adenocarcinoma The expression was related to the clinical features such as gender, age, tumor size and so on (P> 0.05). 3 The positive expression of GRP94 in 24 cases of GRP78 protein positive cases was 18 cases, while in 21 cases of GRP78 protein negative cases, GRP94 protein positive cases were 6 cases, the expression of GRP94 protein in rectal adenocarcinoma was positively correlated rs = 0.464, P <0.01). Conclusions GRP78 and GRP94 proteins are highly expressed in the rectal adenocarcinoma of the cancerous tissue and are related to their metastasis and invasion, which can be used as a useful index to judge the malignant degree of rectal adenocarcinoma.